TTNP - Titan Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.38
-0.12 (-8.33%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.50
Open1.50
Bid1.35 x 10600
Ask1.40 x 1800
Day's Range1.35 - 1.52
52 Week Range1.30 - 4.80
Volume204,441
Avg. Volume213,717
Market Cap29.155M
Beta1.70
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cubeyesterday

    ETFs with exposure to Titan Pharmaceuticals, Inc. : December 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Titan Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to TTNP-US. Comparing the performance and risk of Titan Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Is There Now An Opportunity In Titan Pharmaceuticals Inc (TTNP)?
    Simply Wall St.8 days ago

    Is There Now An Opportunity In Titan Pharmaceuticals Inc (TTNP)?

    Titan Pharmaceuticals Inc (NASDAQ:TTNP), a pharmaceuticals company based in United States, received a lot of attention from a substantial price movement on the NasdaqCM in the over the last fewRead More...

  • Capital Cube12 days ago

    ETFs with exposure to Titan Pharmaceuticals, Inc. : November 30, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Titan Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to TTNP-US. Comparing the performance and risk of Titan Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Titan Pharmaceuticals, Inc. :TTNP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
    Capital Cube13 days ago

    Titan Pharmaceuticals, Inc. :TTNP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017

    Categories: Yahoo FinanceGet free summary analysis Titan Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Titan Pharmaceuticals, Inc. – Vanda Pharmaceuticals Inc., MediciNova, Inc., Celldex Therapeutics, Inc., DURECT Corporation, Paratek Pharmaceuticals Inc, Novartis AG Sponsored ADR, BioDelivery Sciences International, Inc., Johnson & Johnson ... Read more (Read more...)

  • Thomson Reuters StreetEvents29 days ago

    Edited Transcript of TTNP earnings conference call or presentation 9-Nov-17 9:15pm GMT

    Q3 2017 Titan Pharmaceuticals Inc Earnings Call

  • Capital Cubelast month

    ETFs with exposure to Titan Pharmaceuticals, Inc. : November 9, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Titan Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to TTNP-US. Comparing the performance and risk of Titan Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Associated Presslast month

    Titan Pharmaceuticals reports 3Q loss

    On a per-share basis, the San Francisco-based company said it had a loss of 20 cents. The specialty pharmaceutical company posted revenue of $40,000 in the period. The company's shares closed at $1.80. ...

  • Titan Pharmaceuticals, Inc. :TTNP-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
    Capital Cube2 months ago

    Titan Pharmaceuticals, Inc. :TTNP-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017

    Categories: Yahoo FinanceGet free summary analysis Titan Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 0.08 million, Net Earnings of USD -3.45 million. Change in operating cash flow of -118.66% compared to same period last year is about the same as change in earnings, likely no significant ... Read more (Read more...)

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of TTNP earnings conference call or presentation 9-Aug-17 8:15pm GMT

    Q2 2017 Titan Pharmaceuticals Inc Earnings Call

  • How Not to Launch an IPO
    Bloomberg4 months ago

    How Not to Launch an IPO

    Lotte Group's Malaysian plastics unit is an object lesson in over-promising and under-delivering.

  • Zacks Small Cap Research4 months ago

    Titan (TTNP) Reports Second Quarter 2017 Financial and Operational Results

    By John Vandermosten, CFA NASDAQ:TTNP Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) reported second quarter 2017 results on August 9, 2017 in conjunction with the filing of its Form 10-Q.  Total revenues, ...

  • Associated Press4 months ago

    Titan Pharmaceuticals reports 2Q loss

    The San Francisco-based company said it had a loss of 17 cents per share. The specialty pharmaceutical company posted revenue of $77,000 in the period. The company's shares closed at $1.75. A year ago, ...

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of TTNP earnings conference call or presentation 10-May-17 8:15pm GMT

    Q1 2017 Titan Pharmaceuticals Inc Earnings Call

  • Zacks Small Cap Research7 months ago

    TTNP: First Quarter Results; Development Programs on Track.

    By John Vandermosten, CFA NASDAQ:TTNP Titan Reports First Quarter 2017 Financial and Operational Results Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) reported first quarter 2017 results on May 10, 2017 in ...

  • Associated Press7 months ago

    Titan Pharmaceuticals reports 1Q loss

    On a per-share basis, the South San Francisco, California-based company said it had a loss of 16 cents. The specialty pharmaceutical company posted revenue of $40,000 in the period. The company's shares ...

  • Capital Cube7 months ago

    ETFs with exposure to Titan Pharmaceuticals, Inc. : May 5, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Titan Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to TTNP-US. Comparing the performance and risk of Titan Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube9 months ago

    ETFs with exposure to Titan Pharmaceuticals, Inc. : March 27, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Titan Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to TTNP-US. Comparing the performance and risk of Titan Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Zacks Small Cap Research9 months ago

    TTNP: 2016 Results; Deep Dive on Development Programs

    Titan Pharmaceuticals, Inc. (TTNP) reported full-year 2016 results on March 16, 2017 and later participated in an earnings call following the market close.  Total revenues, which consisted of a milestone payment and Probuphine royalties were $15.1 million compared to our estimates of $16.1 million.  The difference was due to fourth quarter royalty revenues of $35,000 vs. our estimates of $1.1 million.  R&D expenses of $6.1 million rose 31% over the prior year due to development expenses related to new ProNeura products. Free cash flow for 2016 was $6.1 million, generated by the $15 million in milestone payments by Braeburn in the second quarter paid upon FDA approval of Probuphine.  Cash levels increased over the year as a result of the positive cash flows from operations, from $7.9 million at the end of 2015 to $14.0 million at year end 2016.

  • Titan Pharmaceuticals, Inc. :TTNP-US: Earnings Analysis: 2016 By the Numbers : March 20, 2017
    Capital Cube9 months ago

    Titan Pharmaceuticals, Inc. :TTNP-US: Earnings Analysis: 2016 By the Numbers : March 20, 2017

    Categories: Yahoo Finance Get free summary analysis Titan Pharmaceuticals, Inc. reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of Titan Pharmaceuticals, Inc. – Vanda Pharmaceuticals Inc., Celldex Therapeutics, Inc., DURECT Corporation, Paratek Pharmaceuticals Inc, Novartis AG Sponsored ADR, Johnson & Johnson and Elite Pharmaceuticals, Inc. (VNDA-US, CLDX-US, ... Read more (Read more...)

  • Associated Press9 months ago

    Titan Pharmaceuticals reports 4Q loss

    The South San Francisco, California-based company said it had a loss of 15 cents per share. The specialty pharmaceutical company posted revenue of $35,000 in the period. For the year, the company reported ...

  • Titan Pharmaceuticals, Inc.: Strong price momentum but will it sustain?
    Capital Cube11 months ago

    Titan Pharmaceuticals, Inc.: Strong price momentum but will it sustain?

    Categories: Yahoo Finance Titan Pharmaceuticals, Inc. relative valuation is NEUTRAL and it has a fundamental analysis score of 58. Our analysis is based on comparing Titan Pharmaceuticals, Inc. with the following peers – Vanda Pharmaceuticals Inc., MediciNova, Inc., Celldex Therapeutics, Inc., Neuralstem, Inc., DURECT Corporation, Paratek Pharmaceuticals Inc, Novartis AG Sponsored ADR, BioDelivery Sciences International, Inc., Johnson & ... Read more (Read more...)